Naučne publikacije akademskog osoblja
Datum kreiranja: 26.02.2014.

Svetislav Vrbić

Dodatne informacije

  • Lični podaci

  • Datum rođenja: 18.08.1957
  • Mesto rođenja: Niš
  • Obrazovanje

  • Fakultet: Medicinski Fakultet u Nišu
  • Odsek / Grupa / Smer: Medicina
  • Godina diplomiranja: 1982.
  • Spisak publikacija

  • Monografije i poglavlja u monografijama:

     1. Novaković M, Babović N,Buta M, Brašanac D, Dimitrijević M, Džodić R, Kandolf-Sekulović L, Magić Z,       Markovič I, Mileusnić D, Mijušković Ž, Nikolin B, Nikolić D, Novaković M, Roš T, Rajović M, Stepić N,        Stevanović G, Šiljan G, Tiodorović-Živković D, Vrbić S, Zolotarevski L. MELANOM KOŽE prevencija,          dijagnostika i lečenje.Akademija medicinskih nauka Srpskog lekarskog društva 2014.

  • Knjige i udžbenici:

    1. Filipović S, Stanojević Z, Vrbić S, Pejčić I. Osnovi kliničke onkologije. Medicinski fakultet Univerziteta u Nišu, Grafika galeb Niš,2009.

    2. Ivica Pejčić, Svetislav Vrbić. Terapija Limfoma, Mutipli mijelom. 233-248, u knjizi Doc.dr Radmila Veličković-Radovanović. FARMAKOTERAPIJA, Galaksija & Medicinski fakultet u Nišu, Niš 2011.


    3. Head and Neck Cancer: Epidemiology, Management and Treatment Outcomes. Side Effects of Cetuximab Rash. Ana Cvetanovic, Sladjana Filipovic, Svetislav Vrbic, Ivica Pejcic, Lazar Popovic, Medical Oncology Unit, University Clinic Nis, Serbia. Madison R.Hall 2015. ISBN: 978-1-63482-113-1



    4. Horizons in Cancer Research. Volume 65: Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A New Key in the Hands of Oncologists. Ana Cvetanovic, Lazar Popovic, Nikola Zivkovic, Gorana Matovina-Brko, Sladjana Filipovic, Kostic Milos, Svetislav Vrbic, Ivica Pejcic, Department of Oncology, University Clinic of Nis, Serbia.Nova Scence Publicher 2017. 

  • Radovi u časopisima sa IMPACT faktorom:

    1. Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M. Current and future anti-HER2 therapy in breast cancer. J BUON 2013;18(1):4-16. IF: 0.761 (M23)
    2. Petric Aleksandra, Stojanov Dragan, Lilic Vekoslav V, Filipovic Sladjana, Bosnjakovic Petar M,
    Zivadinovic Radomir, Lilic Goran, Todorovska I, Vrbic Svetislav, Pejcic Ivica. The application of
    magnetic resonance imaging in preoperative evaluation of patients with endometrial carcinoma. Journal Of BUON 2011; 16(3): 492-497. IF: 0.607 (M23)
    3. Kocic Biljana, Filipovic Sladjana, Vrbic Svetislav, Pejcic Ivica. Breast cancer in women under 40 years of age. Journal of BUON 2011; 16(4): 635-639. IF: 0.607 (M23)
    4. Pejčić Ivica, Vrbić Svetislav, Filipović Sladjana, Šćekić Mirjana, Petković Ivan, Pejčić Ljiljana. Concurrent chemoimmunotherapy: is it still the best option for the treatment of metastatic melanoma in patients with good performance status? Journal Of Buon 2010; 15(3): 470-474. IF: 0.482 (M23)
    5. Ivica Pejčić, Svetislav Vrbić, Sladjana Filipović, Mirjana Šćekić, Ivan Petković, Ljiljana Pejčić, Nebojša Djenić. Značaj praćenja serumskih tumorskih markera kod metastatskih karcinoma nepoznatog primarnog ishodišta. Vojnosanit Pregl 2010; 67(9): 723–731. IF: 0.199 (M23)
    6. Vrbic S, Pejcic I, Vrbic M, Filipovic Sladjana. Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience. Journal Of Buon 2009; 14(1): 41-44. IF: 0.600


    7. S. Vrbic, I. Pejcic, S. Filipovic, B. Kocic, M. Vrbic.Current and future anti-HER2 therapy in breast cancer. J BUON 2013; 18(1): 4-16


    8. A. Cvetanović, S. Vrbić, S. Filipović, I. Pejčić, D. Milenković, N. Živković. Safety and efficacy of addition of bevacizumab to oxaliplati-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. JBUON 2013; 18(3):641-646


    9. Vrbić M, Vrbić S, Škoruć S, Mihailović V, Ranković Ž, Konstantinović Lj, Kostić V, Krstić M, Jovanović M. Solubilni CD4 antigeni u cerebrospinalnoj tečnosti kao marker limfocitne infiltracije centralnog nervnog sistema, Vojnosanit Pregl 2004; 61(3): 247-253


    10. Pejčić I, Vrbić S, Filipović S, Radić S, Pejčić Lj. Chemotherapy in carcinomas of unknown primary site. Journal of BUON 2004;9: 27-31.


    11. Vrbić S, Filipović S, Pejčić I, Vrbić M. Simultaneous or sequential chemotherapy for locally advanced breast cancer. Journal of BUON 2003;8: 317-320


    12. Vrbić S, Filipović S, Pejčić I. Аdjuvant chemotherapy of premenopausal patients and patients under 35 years of age. J BUON 2003; 8 (2): 101-104. 


    13. Vrbić S, Filipović S, Pejčić I,Vrbić M, Filipović A. Sensitivity, specificity, positive and negative predictive value of serum S-100 beta protein in patients with malignant melanoma. Journal of BUON 2003;8: 139-141.


    14.  Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Dusan Milenkovic, Nikola Zivkovic. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.J Buon 2013; 18 (3): 641-646.   .


     15. Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, DusanMilenkovic, Nikola Zivkovic, Milos Kostic, Ivan Petkovic. Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis. JBUON 2014; 19(1): 83-90.


    16. Ivica Pejcic, Ivan Petkovic, Svetislav  Vrbic, Sladjana Filipovic, Mirjana Balic, Ana Cvetanovic. Mantle cell lymphoma-current literature overview. J Buon 2014; 19 (2): 342-349.   IF 0.761   (M23)


    17. Ivica Pejčić, Svetislav Vrbić, Mirjana Todorović, Ivan Petković, Mirjana Balić, Ana Stanković. Sindrom metastatskih tumora nepoznatog primarnog ishodišta-dijagnostičke i terapijske dileme. ACTA FAC MED NAISS 2014;31(2):87-94.


    18. Ivan Petkovic, Ivica Pejcic, Svetislav Vrbic. Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma? Contemp Oncol (Pozn) 2014; ahead of print doi:         PMID:      IF 0,211. 


    19. Lidija Kandolf-Sekulović, Nada Babović, Mirjana Balić, Borislava Nikolin||,Dejan Nikolić, Zlata Janjić, Neven Jokić, Željko Mijušković, MilicaRajović, Marijan Novaković , Svetislav Vrbić, Ivica Pejčić, PredragKovačević, Dragan Mihajlović, Tatjana Roganović, Vicko Ferenc, JelenaNikolić, Marijan Marinković|| , Zorana Bizetić. Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia – the Melanoma Focus Study.VOJNOSANITETSKI PREGLED 2015;72(4):312-316.


     20. Ivan Petković, Miljan Krstić, Ivica Pejcić, Svetislav Vrbić, Slavica Stojnev, Ana Cvetanović, Mirjana Balić, Mirjana Todorović. Renal infiltration of Follicular Lymphoma. Turk J Haematol 2014; 31 (3): 315-6.


    21. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma? Contemp Oncol (Pozn) 2014; 18 (6): 377–383.


     22. Biljana Kocic, Sladjana Filipovic, Svetislav Vrbic, Ivica Pejcic, Natasa Rancic, Ana Cvetanovic, Dusan Milenkovic.  Stressful life events and breast cancer risk: a hospital-based case-control study.  JBUON 2015; 20(2): 487-491.


    23.Ivan Petković, Slavica Stojnev, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić. Sinchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence?  Vojnosanit Pregl 2016; 73 (11): 1072-75. 


    24. Ivan Petković, Ivica Pejčić, Danica Tiodorović, Miljan Krstić, Slavica Stojnev, Svetislav Vrbić. Transformation of primary cutaneous follicle centre lymphoma into primary cutaneous diffuse large B-cell lymphoma of other type. Postepy Dermatol Alergol 2017; a head of print. 


     


     


     


        


     

  • Radovi u ostalim časopisima:

    1. Vrbić M, Vrbić S, Konstantinović Lj, Kostić V, Krstić M, Ranković Ž.  Whole thymus extract (Thymex-L) in the treatment of autoimmune hepatitis, International Journal of Thymology, 1996, 4, (7), 386-389.


    2. Pejčić I, Vrbić S, Filipović B, Petrović M. Serum ferritin levels-a useful marker in Non-Hodgkin Lymphomas? Archive of Oncology 1996;4(2):83-85.


    3. Filipović S, Filipović B, Baltić V, Pejčić I, Vrbić S, Stojanović D, Kocić B, Ljubenković S. Tumour markers Ca 15-3, TPA, CEA as predictive factors in breast cancer patients. Archive of Oncology 1996;4(3):151-154.


    4. Filipović S, Pejčić I, Vrbić S, Jovanović B, Antović J, Bakić M. Blood coagulation and fibrinolysis parameters changes in patients with metastatic melanoma. Archive of Oncology 1998;6(3):93-94.


    5. Vrbić M, Vrbić S, Konstantinović Lj, Ranković Ž, Kostić V, Krstić M. Značaj vrednosti serumskog alfa-fetoproteina u hroničnom hepatitisu C. Acta Infectologica Yugoslavica 2001;6:287-290.


    6. Ivica Pejčić, Svetislav Vrbić. Application of anti-CD20 monoclonal antibodies in the treatment of limfoproliterative diseases. Archive of Onology 2009; 17(3-4):65-67


    7. Ivan petković, Dragan Mihailović, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Burkitt Lymphoma in Elderly Patients. ACTA FACULTATIS MEDIANE NAISSENSIS 2013; 30(2): 103-109


    8. Vrbić M, Vrbić S, Škoruć S, Mihailović V, Ranković Ž, Konstantinović Lj, Kostić V, krstić M, Jovanović M. Beta-2 mikroglobulin kao marker neuronalne destrukcije, Acta Infectologica Yugoslavica, 2004, 8: 23-29.


    9. Ivan Petković, Dragan Mihailović, Miljan Krstić, Ivica pejčić, Svetislav Vrbić, Mirjana Balić. Primary Mantle Cell Lymphoma of Gastrointestinal Tract-a Case Raport. ACTA MEDICA MEDIANE 2012; 3:411-45


    10. Petković I, Pejčić I, Vrbić S. New frontiers of target therapy in oncology: acute promyelocytic leukemia. Acta Fac Med Naiss 2014; 31 (1): 17-28.


     


    .


     

  • Radovi na naučnim skupovima međunarodnog značaja:

    1. Đorđević D, Kostić M, Pejčić I, Vrbić S. Karcinom dojke i pluća. II Pneumoftiziološki dani. Zbornik radova “Malignom pluća”, Niš, 1987:59-65.


    2. Pejčić I, Vrbić S.Androgen receptors and predictors of response to hormonal therapy of prostate cancer. European School of Oncology, Niš 2002. Education Book, Prostate cancer, Pathology and hormonal aspects of diagnosis.


    3. Vrbić S, Pejčić I  Adjuvant chemotherapy of brest cancer patients under 35 years of age. European School of Oncology, Niš 2002. Education Book, Breast cancer, Adjuvant chemotherapy.


    4. Dinić Ž, Filipović D, Filipović S, Radić S, Ćirković S,ProjevićM, Pejčić I, Vrbič S, Lilić Arsić S. Mogućnosti hemioterapijskog uticaja na primarne karcinome bronha i pluća.II Pneumoftiziološki dani. Zbornik radova “Malignom pluća”, Niš, 1987:101-106.


    5. Vlajković M, Ilić S, Pejčić I, Vrbić S, Mihailović D. Karanikolić A, Matović M. Clinical usefulness of 99MTC-EDDA/HYNIC-TOC scintigraphy in diagnosing and          staging of patients with medullary thyroid carcinoma. Thyroid and Parathyroid   Surery/ (Proceedings Book)-Beograd: udruženje onkoloških hirurga Srbije 2008:


    6. Vladimir Kovčin, Dušan Jovanović, Nebojša Manojlović, Svetislav Vrbić, Zoran Andri, Ivan Nikolić, Aleksandra Pantelić, Davorin Radosavljević. Prospective Evaluation of Response and Conversionm-to-Resectability Rate in Patients with Metastatic Colorectal Cancer After 4 Cycles CAPOX/FOLFOX plus Bevaciyumab- Updetad Results from relevant Trial. Annals of Oncology 2011; 22(Suppl 5):101 (P-0292)


    7. VladiMir Kovčin, Nebojša Manojlović, Dušan Jovanović, Svetislav Vrbić, Zoran Andrić, Ivan Nikolić, Aleksandra Pantelić, Tamara Ursulović. The Impact of Capecitabine Dose Modification to Duration of Treatment in Patients with Metastatic colorectal Cancer-First results from AXIOM Trial. Annals of Oncology 2011; 22(Suppl 5):101 (P-0293)


    8. Davorin Radosavljević, Vladimir Kovčin, Svetislav Vrbić, Dušan Jovanović, Dino Tarabar, Marija Ristić, Zafir Murtezani, Aleksandra Pantelić, Ivan Nikolić, Nebojša Manojlović. Conversio.to-Resectability Chemotherapy for Liver Metastasis of Colorectal Cancer: Updated results of RELEVANT Multicenter Trial. Anals of Oncology 2013; 24 (Suppl 4):105 (P-0246)


    9. Vladimir Kovčin, Svetislav Vrbić, Dušan Jovanović, Tamara Ursulović, Nabojša Manojlović, Zoran Andrić, Sanja Kostić, Milan Marković, Ivan Nikolić, Jelena Spasić, Zoran Petrović, Slobodan Milićević. Safety of Capecitabine in Treatment of Patients with Metastatic Colorectal Cancer-Interim Analysis from “AXIOM” Trial. Anals of Oncology 2013; 24 (Suppl 4):106 (P-0250)


    10. B. Mihaljević, D. Jovanović, N. Anđelković, S. Popović, T Vukićević, B Anđelić, L. Popović, M. Todorović, N Vladisavljević, S. Sretenović, S Janković, G Marjanović, S Vrbić, J Hajder, D Zivić. Maximizing Therapeutic Benefit of Rituximab for Relapsed/Resistant Follicular Lymphoma: 2 years Maintence therapz Rasultats. Hematol Oncol 2013;31 (Suppl 1): 221


    11. Kandolf-Sekulović Lidija, Babović N, Nikolin B, Nikolić D, Milosavljević M, Rajović R, Novaković N, Vrbić S, Pejčić I, Kovačević P, Mihajlović D, Raganović T, Vicko F, Nikolić J, Marinković M. Epidemiology, Clinicopathological Characteristic, Diagnosis and Treatment of Melanoma in Serbia-the MELANOMA FOCUS STUDY. 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centers & 8th EADO Congress, 14th-17th November 2012, Barcelona, Spain.

  • Radovi na domaćim naučnim skupovima:

    1. Dinić Ž, Filipović S, Filipović D, Veljković D, Milutinović M, Radić S, Projević M, Pejčić I, Vrbić S. Rezultati primene polihemioterapije (VCR-5FU-CCNU) u bolesnika obolelih od kolorektalnog karcinoma. VII Kongres kancerologa Jugoslavije. Zbornik rezimea. Novi Sad, 1987.


    2. Vrbić S, Pejčić I. Biološka i genska terapija epitelnih karcinoma jajnika. Savremeni pristupu dijagnostici i terapiji karcinoma ovarijuma, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2006: 166-176.


      Petrović M, Pejćić I, Vrbić S, Mišković M, Dinić Ž. Feritin i timidin kinaza (TK) kod pacijenata sa malignim hemopatijama. VIII Kongres kancerologa Jugoslavije. Zbornik reuimea. Zagreb 1991.

    3. Radić S, Filipović S, Projević M, Pejčić I, Filipović B, Vrbić S. Značaj bioloških markera  u praćenju toka i prognoze karcinoma prosatate. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.

    4. Stanić A, Vrbić S, Pejčić I. Neuron specifična enolaza  (NSE) i karcinoembrionalni antigen (CEA) u bolesnika sa malignim tumorima pluća. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.

    5. Dinić Ž, Filipović S, Filipović B, Stojanović Z, Radić S, Petrović M, Vrbić S. Odnos između nivoa tumorskih markera u serumu i ehotomografskih nalaza u metastatskom sindromu jetre. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.

    6. Vrbić S, Filipović S. Imunoterapija THX-om u bolesnica sa karcinomom dojke na zračnoj terapiji-preliminarni rezultati. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.

    7. Filipović S, Filipović B, Vrbić S, Petrović B.Do Ca 15-3 and, or CEA, TPA allow brest cancer metastasis to be predicted before clinical manifestations occur. 5th Breast Cancer Working Conference. Programe and Abstracts. Pauscollege Leuven, Belgium, 1991.

    8. Vrbić S, Filipović S. Immunotherapy affect of THX on certain parameters of cellular immunity in breast cancer patients during local radiation therapy. Congres of Radiology and Oncology, Work in Progres Abstracts, Brighton, 1991.

    9. Pejčić I, Vrbić S, Petrović M, Mišković M. Follow up of the serum feritin values in patients with non Hodgkin lymphomas. The Seventh Europian Conference of Clinical Oncologz and Cancer Nurshing . EU J Cancer 1993; 29a(6):177.

    10. Pejčić I, Petrović M, Vrbić S, Mišković M. Koncentracija serumskog feritina u bolesnika sa limfomima tipa non Hodgkin. XXIX Kancerološka nedelja. Program i zbornik sažetaka. Beograd, 1992.

    11. Vrbić M, ĐorĐević J, Kamenov B, Vrbić S, Vojinović J. Interferonska modifikacija inhibicije migracije leukocita u Down sindromu. Godišnji sastanak udruženja alergologa i kliničkih imunologa Jugoslavije ’94. Zbornik sažetaka. Kragujevac, 1994.

    12. Pejčić I, Vrbić S, Petrović M. Primena rekombinovanog G-CSF u pacijenata sa neutropenijom koja je indukovana citostatskom terapijom. Osnivački kongres hematologa Jugoslavije. Bilten za hematologiju 1994;22(1-2):42.

    13. Vrbić S, Pejčić I, Petrović M. GM-CSF u terapiji pancitopenije izazvane zadesnim preoziranjem Lomustina –prikaz slučaja. Osnivački kongres hematologa Jugoslavije. Bilten za hematologiju 1994;22(1-2):95.

    14. Vrbić M, Kamenov B, Vrbić S, Vojinović J. Down’s syndrome model for analysis of interferon’s action. First Balkan Immunology Conference. Program and Abstract Book. Belgrade,1995.

    15. Filipović S, Filipović B, Veselinović S, Milutinopvić M, Stojanović D, Ilić R, Burić M, Pejčić I, Vrbić S, Potić-Zečavić N, Stojanović Z. Adjuvant chemotherapy in node negative breast cancer patients with cathepsin/D tumours. Journal of B.U.ON. 1996;1(1):20.

    16. Vrbić S, Pejčić I, Petrović M. Adriamycin 90 mg/m2 and cisplatin 90 mg/m2 as primary chemotherapy in disseminated soft tissues sarcomas. . Journal of B.U.ON. 1996;1(1):27

    17. Filipović S, Filipović R, Ilić R, Đorđević S, Vrbić S, Pejčić I, Veselinović S, Stojanović D. Breast Cancer Oestrogen-Receptor Negative Tumors, PS2 Expresion and DFI. 7th EORTC Breast Working Conference. Eu J Cancer 1996;32A(2):57.

    18. Pejčić I, Vrbić S, Filipović S, Petrović M. Vrednost serumskog feritina kao prognostičkog  faktora u limfomima tipa non Hodgkin (NHL). Jugoslovenski hematolođki dani sa međunarodnim učešćem. Abstrakti radova. Niška Banja, 1996.

    19. Veselinović S, Filipović S, Projević M, Stanojević D, Burić M, Filipović S, Pejčić I, Vrbić S. The effects of  tamoxifen on plasma lipid levels in postmenopausal breast cancer patients. Archive of Oncology 1996;4(2):59.

    20. Filipović S, Filipović B, Kocić B, Petrović B, Veselinović S, Pejčić I, Vrbić S, Zečavić NP, Stojanović Z, Stojanović D. The raltionship of follow up tests with occurrence of overt metastatic desease. ECCO 9. Abstracts, Hamburg, 1997.

    21. Vrbić S, Pejčić I, Jovanović B. Naša iskustva u lečenju relapsa i/ili rezistentnih non Hodgkin limfoma intermedijarnog i visokog rizika ESHAP protokolom. 8.Kongres hematologa Jugoslavije sa međunarodnim učćešćem. Zbornik sažetaka. Podgorica, 1998.

    22. Pejčić I, Vrbić S, Antović J, Filipović S, bakić M. Pormećaji koagulacije u bolesnika sa metastatskim tumorima nepoznatog primarnog ishodišta. 8.Kongres hematologa Jugoslavije sa međunarodnim učćešćem. Zbornik sažetaka. Podgorica, 1998.

    23. Pejčić I, Vrbić S, Jovanović B, Filipović S. Altered coagulability in patients with metastatic melanoma. 2nd Balkan Congress of Oncology. Izmir Turkey, 1998.

    24. Vrbić S, Pejčić I, Jovanović B, Filipović S. Our experiences in chemotherapy of diseminated soft tissues sarcoma. XXXV Annual meeting of Oncology. Meeting abstracts. Belgrade, 1998.

    25. Pejčić I, Vrbič S, Jovanović B, Filipović S, Veličković M. Altered parameters of coagulability in patients with metastatic tumours of unknown primary site. XXXVI Annual meeting of Oncology. Meeting abstracts. Belgrade, 1999.


    27. Vrbić S, Pejčić I, Filipović S, Radić S. Sequential dose-dense single agent        chemotherapy for locally advanced breast cancer. Archive of Oncology           2003;11(3):149.


    28. Pejčić I, Vrbić S, Šćekić M. Combined chemotherapy and irradiation in anaplastic thyroid carcinoma. Archive of Oncology 2003;11(3):187.


    29. Vrbić S, Pejčić I. Biološka i genska terapija epitelnih karcinoma jajnika. Savremeni pristupu dijagnostici i terapiji karcinoma ovarijuma, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2006: 166-176.


    30. Pejčić I, Vrbić S. Regulacija angiogeneze kod karcinoma ovarijuma: uloga p53, VEGF i hipoksije. Savremeni pristupu dijagnostici i terapiji Karcinoma ovarijuma, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2006: 103-108.


    31. Simonović S, Vrbić S, Pejčić I, Veličković M. Radioterapija karcinoma tireoideje. Dijagnostika i lečenje diferentovanog karcinoma štitaste žlezde, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2008: 77-85.


    32. Pejčić I, Vrbić S, Šćekić M, Veličković M. Sistemska hemioterapija karcinoma štitaste žlezde. Dijagnostika i lečenje diferentovanog karcinoma štitaste žlezde,   Zbornik radova sa recenzijom, Medicinski fakultet Niš 2008: 87-90.


    33. Nataša Simonović, Svetislav Vrbić, Ivica Pejčić. Medikamentozna onkološka terapija medularnog tireoidnog karcinoma, u Dijagnostika i lečenje medularnog karcinoma štitaste žlezde. Zbornik Radova, Niš 2009; 91-95


    34. B. Mihaljević, D. Jovanović, N. Anđelković, S. Popović, T Vukićević, B Anđelić, L. Popović, M. Todorović, N Vladisavljević, S. Sretenović, S Janković, G Marjanović, S Vrbić, J Hajder, D Zivić. Primena Rituximaba kod bolesnika sa relaps/refraktarnim folikularnim NHL-iskustva Srpske limfomske grupe. 2. Kongres hematologa Srbije  I 6th Balkan Day of Haematology, Knjiga sažetaka November 2011, 166: P148.


    35.Irena Conić, Zorica Stanojević, Nataša Zečevič, Ivica Pejčić, Svetislav Vrbić. Uticaj vrste terapije carcinoma grlića materice na anksioznost. 49. Kancerološka nedelja, Program i zbornik radova; 74:P6


     


       


    .

Poslednji put izmenjeno ponedeljak, 06 februar 2017 11:42